TP53 and neoplasm: Tumours further represented the major molecular risk-groups in current clinical use [22, 31], encompassing favourable (MBWNT and infant DN MBSHH), standard, high- and very high-risk tumours (MYC-amplified MBGroup3 and TP53-mutated MBSHH) [42, 43] (Fig. 1a), and recently described whole-chromosome aberration phenotypes (i.e. Chr 7 + .